NovaDigm Therapeutics, Inc.
http://www.novadigm.net/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NovaDigm Therapeutics, Inc.
Pipeline Watch: Phase III Updates For Eravacycline, Opdivo And Keytruda
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Genocea Aims To Take The T-Cell Century By The Horns
Although cancer grabs the spotlight for harnessing the immune system against tumors, other therapeutic areas and modalities are being developed in the shadows. Genocea Biosciences thinks it has a surefire way to identify novel antigens for T-cell vaccines. It hopes to shake up large infectious disease markets, and more.
Life Science Start-Ups: Tech Transfer Deals, July-August 2014
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June 2014.
Life Science Start-Ups: Venture Funding, November 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2013.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice